Geneva, March 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119489) titled 'Development and Application of a Novel Method for Therapeutic Drug Monitoring of Furmonertinib' on Feb. 27.
Study Type: Observational study
Study Design:
Cross-sectional
Primary Sponsor: Shanghai General Hospital
Condition:
Non-Small Cell Lung Cancer
Recruitment Status: Not Recruiting
Phase: 0
Date of First Enrollment: 2026-03-01
Target Sample Size: Trial group:50;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=311079
Published by HT Digital Content Services with permission from Health Daily Digest....